Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene

Blood

Volumn 123, Issue 25, 2014, Pages 3895-3905

  Zhou, Xiaoou ^a,b   Di Stasi, Antonio ^a,b   Tey, Siok Keen ^a,b   Krance, Robert A ^a,b   Martinez, Caridad ^a,b   Leung, Kathryn S ^a,b   Durett, April G ^a,b   Wu, Meng Fen ^a,b,c   Liu, Hao ^c   Leen, Ann M ^a,b   Savoldo, Barbara ^a,b   Lin, Yu Feng ^a,b   Grilley, Bambi J ^a,b   Gee, Adrian P ^a,b   Spencer, David M ^d   Rooney, Cliona M ^a,b   Heslop, Helen E ^a,b,e   Brenner, Malcolm K ^a,b,e   Dotti, Gianpietro ^b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Bellicum Pharmaceuticals   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; AP 1903; CASPASE 9; CASPOFUNGIN; MICAFUNGIN; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ADENOVIRUS; ADENOVIRUS INFECTION; ADOLESCENT; ARTICLE; BK VIRUS; BK VIRUS INFECTION; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GENE ACTIVATION; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VIVO STUDY; MALE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE; TRANSGENE;

ADOLESCENT; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASPASE 9; CHILD; CHILD, PRESCHOOL; ENZYME INDUCTION; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MYELODYSPLASTIC SYNDROMES; ORGANIC CHEMICALS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; T-LYMPHOCYTES; TIME FACTORS; TRANSGENES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 84902654151     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-551671     Document Type: Article

References (47)

1. Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 2012;119(9):1972-1980.
2. Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program. 2012;2012:230-236.
3. Palma J, Salas L, Carrión F, et al. Haploidentical stem cell transplantation for children with high-risk leukemia. Pediatr Blood Cancer. 2012;59(5):895-901.
4. Kanda J, Long GD, Gasparetto C, et al. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biol Blood Marrow Transplant. 2014;20(2):257-263.
5. Kennedy-Nasser AA, Bollard CM, Myers GD, et al. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008;14(11):1245-1252.
6. Amrolia PJ, Muccioli-Casadei G, Huls H, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006;108(6):1797-1808. (Pubitemid 44394986)
7. Marek A, Stern M, Chalandon Y, et al Swiss Blood Stem Cell Transplantation. The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. Bone Marrow Transplant. 2014;49(1):55-61.
8. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186-1193. (Pubitemid 28482127)
9. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447-3454.
10. Bethge WA, Haegele M, Faul C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol. 2006;34(12):1746-1752. (Pubitemid 44839013)
11. André-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet. 2002;360(9327):130-137. (Pubitemid 34786202)
12. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003;102(6):2292-2299. (Pubitemid 37122412)
13. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114(19):4283-4292.
14. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009;10(5):489-500.
15. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719-1724. (Pubitemid 27421983)
16. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR. Controlling signal transduction with synthetic ligands. Science. 1993;262(5136):1019-1024. (Pubitemid 24035037)
17. Straathof KC, Pulè MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105(11):4247-4254. (Pubitemid 40720769)
18. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(8):913-924. (Pubitemid 47055386)
19. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673-1683.
20. Piantadosi S, Fisher JD, Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol. 1998;41(6):429-436. (Pubitemid 28140705)
21. Iuliucci JD, Oliver SD, Morley S, et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol. 2001;41(8):870-879. (Pubitemid 32692098)
22. Ghetie V, Thorpe P, Ghetie MA, Knowles P, Uhr JW, Vitetta ES. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. J Immunol Methods. 1991;142(2):223-230.
23. Cruz CR, Lam S, Hanley PJ, et al. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013;174(1):89-96.
24. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a realtime PCR assay. J Clin Microbiol. 1999;37(1):132-136. (Pubitemid 29004193)
25. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.
26. Quintarelli C, Vera JF, Savoldo B, et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007;110(8):2793-2802. (Pubitemid 350006931)
27. Arber C, Abhyankar H, Heslop HE, et al. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther. 2013;20(9):958-962.
28. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-763. (Pubitemid 38680440)
29. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(1) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001;27(8):777-783. (Pubitemid 32496409)
30. Eyrich M, Lang P, Lal S, et al. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigendisparate haematopoietic stem cells from parental donors. Br J Haematol. 2001;114(2):422-432. (Pubitemid 32762247)
31. Dvorak CC, Gilman AL, Horn B, et al. Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(1) cells and a fixed CD3(1) dose. Bone Marrow Transplant. 2013;48(4):508-513.
32. Martínez C, Urbano-Ispizua A, Rozman C, et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD341 selected grafts with recipients of unmanipulated grafts. Exp Hematol. 1999;27(3):561-568. (Pubitemid 29125066)
33. Castermans E, Hannon M, Dutrieux J, et al. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica. 2011;96(2):298-306.
34. Vago L, Oliveira G, Bondanza A, et al. T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood. 2012;120(9):1820-1830.
35. Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-celldepleted bone marrow transplantation depends on thymic activity. Blood. 2000;96(6):2299-2303.
36. Kalwak K, Gorczyńska E, Toporski J, et al. Immune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery. Br J Haematol. 2002;118(1):74-89. (Pubitemid 34779519)
37. Chen X, Barfield R, Benaim E, et al. Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients. Blood. 2005;105(2):886-893. (Pubitemid 40070780)
38. Clave E, Busson M, Douay C, et al. Acute graft-versus- host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood. 2009;113(25):6477-6484.
39. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity. 2008;29(6):848-862.
40. Krenger W, Blazar BR, Holländer GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood. 2011;117(25):6768-6776.
41. Toubert A, Glauzy S, Douay C, Clave E. Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens. 2012;79(2):83-89.
42. Ringhoffer S, Rojewski M, Döhner H, Bunjes D, Ringhoffer M. T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/bTREC ratio and thymic naive T cells. Haematologica. 2013;98(10):1600-1608.
43. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)
44. Dey BR, McAfee S, Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2003;9(5):320-329. (Pubitemid 38351817)
45. Ciceri F, Labopin M, Aversa F, et al Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112(9):3574-3581.
46. Munchel A, Kesserwan C, Symons HJ, et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, posttransplantation cyclophosphamide. Pediatr Rep. 2011;3(Suppl 2):e15.
47. Yan CH, Liu DH, Liu KY, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(14):3256-3262.